Testosterone Replacement Therapy Slows Prostate Cancer!

Think again!

Keep reading and discover the latest research on testosterone’s benefits

A recent study finds testosterone replacement slows prostate cancer recurrence in low-risk patients

In the most momentous study so far undertaken, US researchers have found that testosterone replacement slows the return of prostate cancer in low-risk patients.

This finding may question the long-held theory of traditional hormonal prostate treatment. The conclusions were presented at the European Association of Urology congress in Barcelona, Spain.

Background

Doctors have long regarded testosterone as a hormone which promotes prostate cancer. The 1941 work of Dr. Charles Huggins and Clarence Hodges won Huggins the 1966 Nobel Prize for Medicine, for reporting the dramatic impact of testosterone reduction on prostate cancer.

Since then, medicines which reduce levels of the hormone testosterone have become a standard option for many patients.

But the Huggins study has been shown to be severely flawed.

In the late 1990s to 2000s, doctors observed that although men on long term anti-testosterone treatments were not dying from prostate cancer, they were dying prematurely of cardiovascular disease.

It seemed that although anti-testosterone therapies were treating the prostate cancer, the deficient testosterone levels were significantly worsening a parade of metabolic dysfunctions: elevated blood sugar, diabetes, high cholesterol, mid-abdomen visceral fat, fatigue, weakened, shrinking muscles, etc.

Low testosterone also caused a loss of libido and sexual ability in many men on Low-T treatment. This led some doctors to propose testosterone treatment of some low-risk men after radiation or surgical treatment.

The Study

Beginning in 2008 a team of doctors from the University of California, Irvine, led by Professor Thomas Ahlering, began to carefully select patients for testosterone replacement after primary treatment of prostate cancer with robotic radical prostatectomy, in hopes of improving recovery of sexual function.

The team worked with 834 patients undergoing radical prostatectomy. They treated 152 low-risk patients with no evidence of disease with testosterone replacement therapy.

After a median of 3.1 years following surgery, the patients were tested for biochemical recurrence of cancer, as indicated by measurement of the Prostate Specific Antigen (PSA) levels.

They found that cancer had recurred in only approximately 5% of treated patients, whereas cancer had recurred in 15% of the patients who did not receive testosterone. Overall, after accounting for differences between the groups, they found nearly a three-fold reduction by three years.

The Significance of the Study

Thomas Ahlering stated that, "This is not what we set out to prove, so it was a big surprise: not only did testosterone replacement not increase recurrence, but it actually lowered recurrence rates. While the testosterone is not curing the cancer per se, it is slowing the growth of the cancer, giving an average of an extra 1.5 years before traces of cancer can be found. We already know that testosterone can help with physiological markers such as muscle mass, better cholesterol and triglyceride levels, and increased sexual activity, so this seems to be a win-win".

He continued, "There have been smaller studies which have hinted that testosterone may not be risky for certain patient groups, but this is the largest such study ever conducted. We're not suggesting that treatment methods be changed just yet, but this puts us at the stage where we need to question the taboo against testosterone use in prostate cancer therapy -- especially for low-risk patients after radical prostatectomy. We need the oncology/urology community to begin to review testosterone use".

Professor Francesco Montorsi (Milano), European Association of Urology's Adjunct Secretary General for Science said:

"The paper is indeed important, as it stresses the importance of checking testosterone levels as a part of the management of patients with sexual disorders following radical prostatectomy. Obviously selection of the right patients is vital, but if confirmed, this may have immediate benefits on quality of life; the possibility of reducing mortality would be an unexpected bonus. We now need bigger studies to support this work".

This is an objective observation. Professor Montorsi was not directly involved in this work.

Notes

Charles B Huggins

Hormone Therapy for Prostate Cancer

Testosterone slows prostate cancer recurrence in low-risk patients

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.
Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.